VIVUS, Inc. Earnings: What to Expect Monday

Can the obesity-drug maker get out of its slump and start delivering for shareholders?

Feb 22, 2014 at 1:45PM

VIVUS (NASDAQ:VVUS) will release its quarterly report on Monday, and investors haven't been happy with the way that the obesity-drug maker's stock has performed. Despite the huge potential in the obesity-treatment space that sent shares of VIVUS, Arena Pharmaceuticals (NASDAQ:ARNA), and Orexigen Therapeutics (NASDAQ:OREX) soaring in early 2012, VIVUS has seen its stock lose half its value over the past year as its Qsymia drug hasn't lived up to high expectations.


Source: VIVUS.

The poor performance from VIVUS and Arena has been particularly surprising because of the lack of viable obesity drugs in the market before their respective offerings gained approval. Because of that, most analysts expected that sales of both Qsymia and Arena's Belviq would soar once they got FDA approval. Yet struggles to create growth in Qsymia sales have led many investors to give up on VIVUS stock entirely. Let's take an early look at what's been happening with VIVUS over the past quarter and what we're likely to see in its report.

Stats on VIVUS

Analyst EPS Estimate


Year-Ago EPS


Revenue Estimate

$28.2 million

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Can the VIVUS earnings report make investors more confident?
Analysts in recent months have marked down their views on VIVUS earnings, widening their loss expectations by a penny per share for the fourth quarter and $0.02 per share for the full 2014 year. The stock has kept sliding, losing more than 30% of its value since mid-November.

VIVUS started the quarter on a downbeat note, with third-quarter results pointing to the continuing troubling trend of subpar sales growth. More than 75% of the revenue VIVUS brought in during the quarter came from a licensing agreement for its erectile-dysfunction drug avanafil, with Qsymia generating just $6.4 million in sales. In response, the company said it would cut 20 workers, representing about a sixth of its workforce, in order to help reduce overhead costs.

Unfortunately, this quarter might not represent a big turning point for VIVUS. Arena's Belviq sales for the fourth quarter amounted to just $7.5 million, and while that's up almost 40% from the third quarter, it's still just a fraction of what the company had expected. So far, neither company seems to have done a good job convincing doctors that their drugs are a good treatment option for patients, and with health-insurance companies having been reluctant to cover their cost, VIVUS and Arena's marketing partner Eisai have been in the tough position of having to offer discounts to keep customers.

Further competition is also on its way, as Orexigen's Contrave is expected to come up for FDA by mid-year. Like Belviq, Contrave doesn't produce as much weight loss as Qsymia does, but it also has a more attractive safety profile than the VIVUS drug. Yet some believe that Contrave could actually help Qsymia sales by drawing more attention to the obesity-drug space overall.

VIVUS is also making further efforts to boost its prospects. Last month, the company said it would work with health insurer Aetna (NYSE:AET) on a weight-loss program for the insurance company's members in hopes of boosting Qsymia's sales. Moreover, with a licensing deal with Auxilium Pharmaceuticals (NASDAQ:AUXL) to market Stendra, one of avanafil's brand names, VIVUS will bring in $30 million in upfront payments and as much as $300 million in future milestone payments.

In the VIVUS earnings report, watch to see what the company's plans are for adding sales. With CEO Seth Fisher having said that he hopes to get Medicare Part D coverage for Qsymia, it'll be interesting to see what other tricks VIVUS might have up its sleeve to try to restore investor confidence in the company.

Looking beyond obesity
Obesity drugs haven't panned out the way many had expected, and now, some believe that best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add VIVUS to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information